- Home
- MYN vs NGEN Comparison
MYN vs NGEN Comparison
Compare MYN & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | MYN | NGEN |
|---|---|---|
| Founded | 1992 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance Companies | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 380.8M | 317.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MYN | NGEN |
|---|---|---|
| Price | $9.99 | $4.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 196.8K | 107.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.13 | $3.73 |
| 52 Week High | $10.26 | $5.93 |
Technical Indicators
Market Signals| Indicator | MYN | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 42.05 | 40.77 |
| Support Level | $9.90 | $3.76 |
| Resistance Level | $10.21 | $4.50 |
| Average True Range (ATR) | 0.07 | 0.27 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 8.33 | 33.57 |
Price Performance
Historical ComparisonAbout MYN Blackrock MuniYield New York Quality Fund Inc.
Blackrock Muniyield NY Quality FD, Inc is a closed-end management investment company. Its objective is to provide shareholders with a high level of current income exempt from federal income taxes. The Fund invests in long-term municipal obligations that are investment grade quality or are considered by the Fund's investment adviser to be of comparable quality, at the time of investment.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.